Evidence map›Paper›PMID 35426444›Full record

ArticleBiometrics2023

Robust approach to combining multiple markers to improve surrogacy.

Xuan Wang, Layla Parast, Larry Han, Lu Tian, Tianxi Cai

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Biometrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Xuan WangDepartment of Biostatistics, Harvard University, Boston, Massachusetts, USA.ORCID 0000-0002-0011-5663
Layla ParastDepartment of Statistics and Data Sciences, The University of Texas at Austin, Austin, Texas, USA.ORCID 0000-0002-7288-1009
Larry HanDepartment of Biostatistics, Harvard University, Boston, Massachusetts, USA.ORCID 0000-0002-0577-9661
Lu TianDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.ORCID 0000-0002-5893-0169
Tianxi CaiDepartment of Biostatistics, Harvard University, Boston, Massachusetts, USA.
Harvard University · USStanford University · USThe University of Texas at Austin · US

Funding

Scientific & Technical CoreP2CHD042849 · NICHD · UNIVERSITY OF TEXAS AT AUSTIN · PI Elizabeth T. Gershoff · 2017 to 2026
$5.2M
Robust Statistical Methods to Identify and Use Surrogate Markers in DiabetesR01DK118354 · NIDDK · UNIVERSITY OF TEXAS AT AUSTIN · PI PARAST, LAYLA · 2018 to 2025
$2.0M
NICHD NIH HHS P2C HD042849NIDDK NIH HHS R01 DK118354
6 · The paper itself

Abstract

Identifying effective and valid surrogate markers to make inference about a treatment effect on long-term outcomes is an important step in improving the efficiency of clinical trials. Replacing a long-term outcome with short-term and/or cheaper surrogate markers can potentially shorten study duration and reduce trial costs. There is sizable statistical literature on methods to quantify the effectiveness of a single surrogate marker. Both parametric and nonparametric approaches have been well developed for different outcome types. However, when there are multiple markers available, methods for combining markers to construct a composite marker with improved surrogacy remain limited. In this paper, building on top of the optimal transformation framework of Wang et al. (2020), we propose a novel calibrated model fusion approach to optimally combine multiple markers to improve surrogacy. Specifically, we obtain two initial estimates of optimal composite scores of the markers based on two sets of models with one set approximating the underlying data distribution and the other directly approximating the optimal transformation function. We then estimate an optimal calibrated combination of the two estimated scores which ensures both validity of the final combined score and optimality with respect to the proportion of treatment effect explained by the final combined score. This approach is unique in that it identifies an optimal combination of the multiple surrogates without strictly relying on parametric assumptions while borrowing modeling strategies to avoid fully nonparametric estimation which is subject to the curse of dimensionality. Our identified optimal transformation can also be used to directly quantify the surrogacy of this identified combined score. Theoretical properties of the proposed estimators are derived, and the finite sample performance of the proposed method is evaluated through simulation studies. We further illustrate the proposed method using data from the Diabetes Prevention Program study.

Indexed as

Models, StatisticalBiomarkersComputer SimulationBiomarkersmultiple surrogate markersnonparametric estimationproportion of treatment effect explained

Identifiers

PMID35426444
PMCPMC10347081
OpenAlexW4224080885

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.